Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset

Fanny Lanternier(Hôpital Necker-Enfants Malades), Annick Cohen-Akenine(Association Francaise contre les Myopathies), Fabienne Palmérini(Institut Paoli-Calmettes), Frédéric Féger(Laboratoire de Biologie et Pharmacologie Appliquée), Ying Yang(Centre de Recherche en Cancérologie de Marseille), Yaël Zermati(Hôpital Lariboisière), Stéphane Barète(Assistance Publique – Hôpitaux de Paris), B. Sans(Hôpital Larrey), Cédric Baude(Association Francaise contre les Myopathies), David Ghez(Hôpital Necker-Enfants Malades), Felipe Suárez(Université Paris Cité), Richard Delarue(Hôpital Necker-Enfants Malades), Philippe Casassus(Hôpital Avicenne), Christine Bodemer(Université Paris Cité), Adeline Catteau(Association Francaise contre les Myopathies), Frédérique Soppelsa(Association Francaise contre les Myopathies), Katia Hanssens(Association Francaise contre les Myopathies), Michel Arock(Centre National de la Recherche Scientifique), Hagay Sobol(Centre de Recherche en Cancérologie de Marseille), Sylvie Fraïtag(Hôpital Necker-Enfants Malades), D. Canioni(Hôpital Necker-Enfants Malades), Alain Moussy(Association Francaise contre les Myopathies), Jean Marie Launay(Hôpital Lariboisière), Patrice Dubreuil(Institut de Neurobiologie de la Méditerranée), Olivier Hermine(Centre National de la Recherche Scientifique), Olivier Lortholary(Université Paris Cité), for the AFIRMM network
PLoS ONE
April 8, 2008
Cited by 166Open Access
Full Text

Abstract

Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease started during childhood (Group 1, n = 28) with those of patients whose disease started at adult's age (Group 2, n = 114). Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42% and 77% of patients in groups 1 and 2, respectively (p<0.001). 816 c-kit mutation was associated with systemic mastocytosis in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p = 0.0001). Other c-kit activating mutations were found in 23% of patients with mastocytosis' onset before the age of 5, 0% between 6 and 15 years and 2% at adults' age (p<0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the age of disease's onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy.


Related Papers

No related papers found

Powered by citation graph analysis